Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

4 Issues per year


IMPACT FACTOR 2016: 1.288
5-year IMPACT FACTOR: 1.600

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854

Open Access
Online
ISSN
1846-9558
See all formats and pricing
More options …
Volume 63, Issue 3 (Sep 2013)

Issues

Drug interactions with statins

Anida Causevic-Ramosevac
  • Corresponding author
  • Bosnalijek, Pharmaceutical and Chemical Industry, Joint Stock Company, arajevo Bosnia and Herzegovina
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Sabina Semiz
  • Faculty of Pharmacy University of Sarajevo, Sarajevo Bosnia and Herzegovina
  • Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo Bosnia and Herzegovina
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2013-10-22 | DOI: https://doi.org/10.2478/acph-2013-0022

Abstract

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally well tolerated as monotherapy. Statins are associated with two important adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. Statins are substrates of multiple drug transporters (including OAT- -P1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occur due to interactions in concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review summarizes the most important interactions of statins.

Keywords: statins; drug interactions; cytochrome P450 (CYP) enzymes; drug transporters; adverse effects

  • 1. R. J. Herman, Drug interactions and the statins, CMAJ 161 (1999) 1281-1286.Google Scholar

  • 2. Cardiovascular Drugs, in Martindale: The Complete Drug Reference, 36th ed. (Ed. S. C. Sweetman), Pharmaceutical Press, London 2009, pp. 1155-1434.Google Scholar

  • 3. T. Uno, K. Sugimoto, K. Sugawara and T. Tateishi, The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazol, Ther. Drug Monit. 30 (2008) 276-281; DOI: 10.1097/FTD.0b013e31816e2d8e.CrossrefGoogle Scholar

  • 4. C. Bolego, R. Baetta, S. Bellosta, A. Corsini and R. Paoletti, Safety considerations for statins, Curr. Opin. Lipidol. 13 (2002) 637-644.CrossrefGoogle Scholar

  • 5. H. M. Devold, E. Molden, S. Skurtveit and K. Furu, Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy, Br. J. Clin. Pharmacol. 67 (2009) 234-241; DOI: 10.1111/j.1365-2125.2008.03345.x.CrossrefGoogle Scholar

  • 6. E. Molden, K. S. Andersson and D. Jacobsen, Interactions between statins and macrolide antibiotics, Tidsskr. Nor. Laegeforen 127 (2007) 1660-1661.Google Scholar

  • 7. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paolett and F. Bernini, New insights into the pharmacodynamic and pharmacokinetic properties of statins, Pharmacol. Ther. 84 (1999) 413-428.CrossrefGoogle Scholar

  • 8. C. M. White, A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin, J. Clin. Pharmacol. 42 (2002) 963-970.CrossrefGoogle Scholar

  • 9. R. Bhindi, O. Ormerod, J. Newton, A. P. Banning and L. Tesla, Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 101 (2008) 915-925; DOI: 10.1093/qjmed/ hcn089.CrossrefGoogle Scholar

  • 10. P. J. Neuvonen, M. Niemi and J. T. Backman, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance, Clin. Pharmacol. Ther. 80 (2006) 565-581.CrossrefGoogle Scholar

  • 11. K. M. Giacomini, S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. M. Hillgren, K. A. Hoffmaster, T. Ishikawa, D. Keppler, R. B. Kim, C. A. Lee, M. Niemi, J. W. Polli, Y. Sugiyama, P. W. Swaan, J. A. Ware, S. H. Wright, S. W. Yee, M. J. Zamek-Gliszczynski and L. Zhang, Membrane transporters in drug development, Nat. Rev. Drug Discov. 9 (2010) 215-236; DOI: 10.1038/nrd3028.CrossrefGoogle Scholar

  • 12. M. Karlgren, G. Ahlin, C. A. Bergström, R. Svensson, J. Palm and P. Artursson, In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions, Pharm. Res. 29 (2012) 411-426; DOI: 10.1007/s11095-011-0564-9.CrossrefGoogle Scholar

  • 13. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop and R. Collins, SLCO1B1 variants and statin-induced myopathy - a genomewide study, N. Engl. J. Med.359 (2008) 789-799; DOI: 10.1056/NEJMoa0801936.CrossrefGoogle Scholar

  • 14. D. Voora, S. H. Shah, I. Spasojevic, S. Ali, C. R. Reed, B. A. Salisbury and G. S. Ginsburg, The SLCO1B1*5 genetic variant is associated with statin-induced side effects, J. Am. Coll. Cardiol. 54 (2009) 1609-1616; DOI: 10.1016/j.jacc.2009.04.053.CrossrefGoogle Scholar

  • 15. J. P. F. Bai, Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics, Drug Metab. Pharmacokin. 25 (2010) 62-71.CrossrefGoogle Scholar

  • 16. J. Mwinyi, A. Johne, S. Bauer, I. Roots and T. Gerloff, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetic, Clin. Pharmacol. Ther. 75 (2004) 415-421.CrossrefGoogle Scholar

  • 17. M. Niemi, E. Schaeffeler, T. Lang, M. F. Fromm, M. Neuvonen, C. Kyrklund, J. T. Backman, R. Kerb, M. Schwab, P. J. Neuvonen, M. Eichelbaum and K. T. Kivistö, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1), Pharmacogenetics 14 (2004) 429-440.CrossrefGoogle Scholar

  • 18. Y. Shitara, Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions, Drug Metab. Pharmacokin. 26 (2011) 220-227; DOI: 10.2133/dmpk.DMPK-10-RV-094.CrossrefGoogle Scholar

  • 19. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa and K. Chib, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy, Drug Metab. Pharmacokin. 19 (2004) 453-455.CrossrefGoogle Scholar

  • 20. Y. Y. Lau, H. Okochi, Y. Huang and L. Z. Benet, Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems, J. Pharmacol. Exp. Ther. 316 (2006) 762-771.Google Scholar

  • 21. G. A. Schmidt, J. D. Hoehns, J. L. Purcell, R. L. Friedman and Y. Elhawi, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir, J. Am. Board. Fam. Med. 20 (2007) 411-416.CrossrefGoogle Scholar

  • 22. V. Borders-Hemphill, Concurrent use of statins and amiodarone, Consult. Pharm. 24 (2009) 372-379.CrossrefGoogle Scholar

  • 23. S. Lam, N. Partovi, L. S. Ting, and M. H. Ensom, Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?, Ann. Pharmacother. 42 (2008) 1037-1047; DOI: 10.1345/aph.1K628.CrossrefGoogle Scholar

  • 24. D. Williams and J. Freely, Pharmacokinetic-pharmacodynamic drug interactions with HMGCoA reductase inhibitors, Clin. Pharmacokinet. 41 (2002) 343-370.CrossrefGoogle Scholar

  • 25. S. Bellosta, R. Paoletti and A. Corsini, Safety of statins: focus on clinical pharmacokinetics and drug interactions, Circulation 109 (2004) III50-III57; DOI: 10.1161/01.CIR.0000131519.15067.1f.CrossrefGoogle Scholar

  • 26. K. Ohyama, M. Nakajima, M. Suzuki, N. Shimada, H. Yamazaki and T. Yokoi, Inhibitory effects of amiodarone and its N-desethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions, Br. J. Clin. Pharmacol. 49 (2000) 244-253.Google Scholar

  • 27. U. M. Chouhan, S. Chakrabarti and L. J. Millward, Simvastatin interaction with clarithromycin and amiodarone causing myositis, Ann. Pharmacother. 39 (2005) 1760-1761.CrossrefGoogle Scholar

  • 28. A. Marot, J. Morelle, V. A. Chouinard, M. Jadoul, M. Lambert and N. Demoulin, Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature, Acta Clin. Belg. 66 (2011) 134-136.Google Scholar

  • 29. B. Ricaurte, A. Guirguis, H. C. Taylor and D. Zabriskie, Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity, Ann. Pharmacother. 40 (2006) 753-757.CrossrefGoogle Scholar

  • 30. A. Alsheikh-Ali and R. Karas, Adverse events with concomitant amiodarone and statin therapy, Prev. Cardiol. 8 (2005) 95-97.Google Scholar

  • 31. S. Karimi, A. Hough, C. Beckey and D. Parra, Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center, J. Manag. Care Pharm. 16 (2010) 472-481.CrossrefGoogle Scholar

  • 32. DRUGDEX®/MICROMEDEX®. Statins. Healthcare Series for Windows. Micromedex Thomson Healthcare. 2012. Retrieved from:http://www.thomsonhc.com/home/dispatch (accessed July 6, 2012).Google Scholar

  • 33. G. W. Amsden, O. Kuye and G. C. Wei, A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers, J. Clin. Pharmacol. 42 (2002) 444-449.CrossrefGoogle Scholar

  • 34. G. W. Amsden, Macrolides versus azalides: a drug interaction update, Ann. Pharmacother. 29 (1995) 906-917.Google Scholar

  • 35. M. P. Pai, D. M. Graci and G. W. Amsden, Macrolide drug interactions: an update, Ann. Pharmacother.34 (2000) 495-513.CrossrefGoogle Scholar

  • 36. J. W. Grunden and K. A. Fisher, Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin, Ann. Pharmacother. 31 (1997) 859-863.Google Scholar

  • 37. M. Z. Skrabal, J. A. Stading, C. A. Cannella and M. S. Monaghan, Two cases of rhabdomyolysis associated with high-dose simvastatin, Am. J. Health. Syst. Pharm. 60 (2003) 578-581.Google Scholar

  • 38. J. Strandell, A. Bate, S. Hägg and I. R. Edwards, Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction, Br. J. Clin. Pharmacol. 68 (2009) 427-434; DOI: 10.1111/j. 1365-2125.2009.03473.x.CrossrefGoogle Scholar

  • 39. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood and G. R. Wilkinson, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein, Pharm. Res. 16 (1999) 408-414.Google Scholar

  • 40. C. Marzolini, E. Paus, T. Buclin and R. B. Kim, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance, Clin. Pharmacol. Ther. 75 (2004) 13-33.CrossrefGoogle Scholar

  • 41. S. Eberl, I. Bachmakov, F. Dörje and M. F. Fromm, The effect of macrolide antibiotics on the function of the drug transporter P-glycoprotein, Naunyn-Schmiedeberg’s Arch. Pharmacol. 371 (2005) R145.Google Scholar

  • 42. J. Rengelshausen, C. Goggelmann, J. Burhenne, K. D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack and W. Haefeli, Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction, Br. J. Clin. Pharmacol. 56 (2003) 32-38.CrossrefGoogle Scholar

  • 43. T. Jacobson, Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors, Am. J. Cardiol. 94 (2004) 1140-1146.Google Scholar

  • 44. A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, N. B. Wolf, F. Dörje, M. F. Fromm and J. König, The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3, Drug Metab. Dispos. 35 (2007) 779-786.CrossrefGoogle Scholar

  • 45. M. Hirano, K. Maeda, Y. Shitara and Y. Sugiyama, Drug-drug interaction between pitavastatin and various drugs via OATP1B1, Drug Metab. Dispos. 34 (2006) 1229-1236.Google Scholar

  • 46. R. D. Sawant, Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin, Can. J. Clin. Pharmacol. 16 (2009) 78-79.Google Scholar

  • 47. M. Ishigami, M. Uchiyama, T. Kondo, H. Iwabuchi, S. Inoue, W. Takasaki, T. Ikeda, T. Komai, K. Ito and Y. Sugiyama, Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions, Pharm. Res. 18 (2001) 622-631.CrossrefGoogle Scholar

  • 48. K. T. Kivistö, T. Kantola and P. J. Neuvonen, Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, Br. J. Clin. Pharmacol. 46 (1998) 49-53.Google Scholar

  • 49. K. Akram, S. Rao and M. Parker, A lesson for everyone in drug-drug interactions (letter), Int. J. Cardiol. 118 (2007) 19-20.Google Scholar

  • 50. R. Gilad and Y. Lampl, Rhabdomyolysis induced by simvastatin and ketoconazole treatment, Clin. Neuropharmacol. 22 (1999) 295-297.Google Scholar

  • 51. H. Itakura, D. Vaughn, D. Haller and P. O’Dwyer, Rhabdomyolysis from cytochrome P-450 interaction of ketoconazole and simvastatin in prostate cancer, J. Urol. 169 (2003) 613; DOI: 10. 1016/S0022-5347(05)63967-5.CrossrefGoogle Scholar

  • 52. C. Stein, S. Goel and R. Ghavamian, Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy, Invest. New Drugs25 (2007) 277-278.Google Scholar

  • 53. O. Findling, N. Meier, J. Sellner, K. Nedeltchev and M. Arnold, Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole, Neurology 71 (2008) 34-37; DOI: 10.1212/01.wnl.0000327566.57661.09.CrossrefGoogle Scholar

  • 54. C. C. Franz, M. Bruggisser, S. Krähenbühl and A. E. Rätz Bravo, Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole, Praxis (Bern 1994) 100 (2011) 273-284; DOI: 10.1024/1661-8157/a000491.CrossrefGoogle Scholar

  • 55. R. Hazin, J. Y. Abuzetun, M. Suker and J. Porter, Rhabdomyolysis induced by simvastatin-fluconazole combination, J. Natl. Med. Assoc. 100 (2008) 444-446.CrossrefGoogle Scholar

  • 56. A. Shaukat, M. Benekli, G. D. Vladutiu, J. L. Slack, M. Wetzler and M. R. Baer, Simvastatin-fluconazole causing rhabdomyolysis, Ann. Pharmacother. 37 (2003) 1032-1035.CrossrefGoogle Scholar

  • 57. N. E. Azie, D. C. Brater, P. A. Becker, D. R. Jones and S. D. Hall, The interaction of diltiazem with lovastatin and pravastatin, Clin. Pharmacol. Ther. 64 (1998) 369-377.CrossrefGoogle Scholar

  • 58. O. Mousa, D. C. Brater, K. J. Sunblad and S. D. Hall, The interaction of diltiazem with simvastatin, Clin. Pharmacol. Ther. 67 (2000) 267-274.CrossrefGoogle Scholar

  • 59. Y. Sugiyama, N. Mimura, T. Kuwabara, H. Kobayashi, J. Ushiki and E. Fuse, Effect of benidipine on simvastatin metabolism in human liver microsomes, Drug Metab. Pharmacokinet. 22 (2007) 199-205.CrossrefGoogle Scholar

  • 60. J. J. Lewin, J. M. Nappi and M. H. Taylor, Rhabdomyolysis with concurrent atorvastatin and diltiazem, Ann. Pharmacother. 36 (2002) 1546-1549.CrossrefGoogle Scholar

  • 61. R. Peces and A. Pobes, Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem, Nephron. 89 (2001) 117-118.CrossrefGoogle Scholar

  • 62. T. Prueksaritanont, B. Ma, C. Tang, Y. Meng, C. Assang, P. Lu, P. J. Reider, J. H. Lin and T. A. Baillie, Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations, Br. J. Clin. Pharmacol. 47 (1999) 291-298.Google Scholar

  • 63. M. Jasiñska, J. Owczarek and D. Orszulak-Michalak, The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study, Acta Pol. Pharm. 63 (2006) 386-390.Google Scholar

  • 64. T. Kantola, K. T. Kivisto and P. J. Neuvonen, Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 64 (1998) 177-182.CrossrefGoogle Scholar

  • 65. H. Satoh, F. Yamashita, M. Tsujimoto, H. Murakami, N. Koyabu, H. Ohtani and Y. Sawada, Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B, DrugMetab. Dispos. 33 (2005) 518-523.CrossrefGoogle Scholar

  • 66. P. Li, P. S. Callery, L. S. Gan and S. K. Balani, Estearase inhibition by grapefruit juice flavonoids leading to a new drug interaction, Drug Metab. Dispos. 35 (2007) 1203-1208.CrossrefGoogle Scholar

  • 67. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin, Clin. Pharmacol. Ther. 66 (1999) 118-127.CrossrefGoogle Scholar

  • 68. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors, Clin. Pharmacol. Ther. 64 (1998) 477-483.CrossrefGoogle Scholar

  • 69. J. J. Lilja, M. Neuvonen and P. J. Neuvonen, Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin, Br. J. Clin. Pharmacol. 58 (2004) 56-60.CrossrefGoogle Scholar

  • 70. I. Fukazawa, N. Uchida, E. Uchida and H. Yasuhara, Effects of grapefruit on pharmacokinetics of atorvastatin and pravastatin in Japanese, Br. J. Clin. Pharmacol. 57 (2003) 448-455.Google Scholar

  • 71. H. Ando, S. Tsuruoka, H. Yanagihara, K. Sugimoto, M. Miyata, Y. Yamazoe, T. Takamura, S. Kaneko and A. Fujimura, Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin, Br. J. Pharmacol. 60 (2005) 494-497.Google Scholar

  • 72. Y. Koitabashi, T. Kumai, N. Matsumoto and M. Watanabe, Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects, Life Sci. 78 (2006) 2852-2859.CrossrefGoogle Scholar

  • 73. A. V. Sorokin, B. Duncan, R. Panetta and P. D. Thompson, Rhabdomyolysis associated with pomegranate juice consumption, Am. J. Cardiol. 98 (2006) 705-706.CrossrefGoogle Scholar

  • 74. T. Hasunuma, M. Nakamura, T. Yachi, N. Arisawa, K. Fukushima, H. Iijima and Saito Y. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine, J. Clin. Ther. Med. 19 (2003) 381-389.Google Scholar

  • 75. Y. Shitara, T. Itoh, H. Sato, A. P. Li and Y. Sugiyam, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A, J. Pharmacol. Exp. Ther. 304 (2003) 610-616.CrossrefGoogle Scholar

  • 76. S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass and D. W. Schneck, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine, Clin. Pharmacol. Ther. 76 (2004) 167-177.CrossrefGoogle Scholar

  • 77. J. Tong, G. Laport and R. Lowsky, Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma, Bone Marrow Transplant. 36 (2005) 739-740.Google Scholar

  • 78. A. Lasocki, B. Vote, R. Fassett and E. Zamir, Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis, Ocul. Immunol. Inflamm. 15 (2007) 345-346.CrossrefGoogle Scholar

  • 79. S. Vives, M. Batlle, E. Montané and J. M. Ribera, Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient, Med. Clin. (Barc). 131 (2008) 676.CrossrefGoogle Scholar

  • 80. J. W. Park, R. Siekmeier, M. Merz, B. Krell, S. Harder, W. März, D. Seidel, S. Schüler and W. Gross, Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A, Int. J. Clin. Pharmacol. Therapeut. 40 (2002) 439-450.Google Scholar

  • 81. M. Veeraputhiran and M. Sundermeyer, Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin, Clin. Lung Cancer 9 (2008) 232-234; DOI: 10.3816/CLC. 2008.n.036.CrossrefGoogle Scholar

  • 82. P. F. Katsakiori, E. P. Papapetrou, D. S. Goumenos, G. C. Nikiforidis and C. S. Flordellis, Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients, Indian J. Pharmacol. 43 (2011) 385-388; DOI: 10.4103/0253-7613.83106.CrossrefGoogle Scholar

  • 83. R. H. Jacobson, P. Wang and C. J. Glueck, Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone, JAMA. 277 (1997) 296-297.CrossrefGoogle Scholar

  • 84. N. S. Karnik and J. R. Maldonado, Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminiti, Psychosomatics46 (2005) 565-568.CrossrefGoogle Scholar

  • 85. Serzone (nefazodone hydrochloride) US prescribing information, Bristol-Myers Squibb Company, January 2005.Google Scholar

  • 86. C. B. Hare, M. P. Vu, C. Grunfeld and H. W. Lampiris, Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death, Clin. Infect. Dis. 35 (2002) 111-112.CrossrefGoogle Scholar

  • 87. P. E. Sax, Strategies for management and treatment of dyslipidemia in HIV/AIDS, AIDS Care 18 (2006) 149-157.CrossrefGoogle Scholar

  • 88. P. H. Hsyu, M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis and B. M. Kerr, Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin, Antimicrob. Agents Chemother. 4 (2001) 3445-3450.Google Scholar

  • 89. R. A. Carr, A. K. Andre, R. J. Bertz, W. Lam, M. Chang, P. Chen, P. Williams, B. Bernstein and E. Sun, Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin, 40th ICAAC, Toronto, September 2000, presentation 1644.Google Scholar

  • 90. C. J. Fichtenbaum, J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, F. Aweeka and NIAID AIDS Clinical Trials Group, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047, AIDS 16 (2002) 569-577.Google Scholar

  • 91. J. A. Aberg, S. L. Rosenkranz, C. J. Fichtenbaum, B. L. Alston, S. W. Brobst, Y. Segal, J. G. Gerber and ACTG A5108 team, Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108, AIDS 20 (2006) 725-729.Google Scholar

  • 92. P. A. Pham, C. J. la Porte L. S., Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner and D. W. Cameron, Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers, Antimicrob. Agents Chemother. 53 (2009) 4385-4392; DOI: 10.1128/AAC.00449-09.CrossrefGoogle Scholar

  • 93. R. Stern, R. Abel, G. L. Gibson and J. Besserer, Atorvastatin does not alter the anticoagulant activity of warfarin, J. Clin. Pharmacol. 37 (1997) 1062-1064.CrossrefGoogle Scholar

  • 94. H. Hickmott, H. Wynne and F. Kamali, The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements, Thromb. Haemost. 89 (2003) 949-950.Google Scholar

  • 95. J. C. Lin, M. K. Ito, S. N. Stolley, A. P. Morreale and D. B. Marcus, The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin, J. Clin. Pharmacol. 39 (1999) 86-90.CrossrefGoogle Scholar

  • 96. E. A. Sconce, T. I. Khan, A. K. Daly, H. A. Wynne and F. Kamali, The impact of simvastatin on warfarin disposition and dose requirements, J. Thromb. Haemost. 4 (2006) 1422-1424.CrossrefGoogle Scholar

  • 97. T. Westergren, P. Johansson and E. Molden, Probable warfarin-simvastatin interaction, Ann. Pharmacother. 41 (2007) 1292-1295.CrossrefGoogle Scholar

  • 98. S. Ahmad, Lovastatin warfarin interaction, Arch. Intern. Med. 150 (1990) 2407.CrossrefGoogle Scholar

  • 99. H. S. Hoffman, The interaction of lovastatin and warfarin, Conn. Med. 56 (1992) 107.Google Scholar

  • 100. E. A. Iliadis and M. F. Konwinski, Lovastatin during warfarin therapy resulting in bleeding, PAMed. 98 (1995) 31.Google Scholar

  • 101. S. S. Kline and C. C. Harrell, Potential warfarin-fluvastatin interaction, Ann. Pharmacother. 31 (1997) 790.Google Scholar

  • 102. L. E. Trilli, C. L. Kelley, S. L. Aspinall and B. A. Kroner, Potential interaction between warfarin and fluvastatin, Ann. Pharmacother. 30 (1996) 1399-1402.Google Scholar

  • 103. M. J. Murphy and M. H. Dominiczak, Efficacy of statin therapy: possible effect of phenytoin, Postgrad. Med. J. 75 (1999) 359-360.CrossrefGoogle Scholar

  • 104. K. M. Tan, J. G. Kelly and K. McGarry, Statins and phenytoin interact - a case history, Br. J. Clin. Pharmacol. 65 (2008) 147-148.CrossrefGoogle Scholar

  • 105. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther. 68 (2000) 592-597.CrossrefGoogle Scholar

  • 106. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects, Br. J. Clin. Pharmacol. 57 (2004) 181-187.Google Scholar

  • 107. R. Eggertsen, A. Andreasson and L. Andrén, Effects of treatment with a commercially available St John’s Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin, Scand. J. Prim. Health Care 25 (2007).Google Scholar

  • 108. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada, M. Arakawa, K.\ Sakamoto, M. Masada, I. Miyamori and A. Fujimura, Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin, Clin. Pharmacol. Ther. 70 (2001) 518-524.CrossrefGoogle Scholar

  • 109. W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G. Carville, K. E. Guyer and E. R. Bates, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation 107 (2003) 32-37.CrossrefGoogle Scholar

  • 110. A. Blagojevic, J. A. Delaney, L. E. Lévesque, N. Dendukuri, J. F. Boivin and J. M. Brophy, Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study, Pharmacoepidemiol. Drug Saf. 18 (2009) 362-369; DOI: 10.1002/pds.1716.CrossrefGoogle Scholar

  • 111. O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, A. Schömig and A. Kastrati, Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting, Eur. Heart J. 25 (2004) 1898-1902.CrossrefGoogle Scholar

  • 112. J. V. Mitsios, A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos and A. D. Tselepis, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes, Circulation 109 (2004) 1335-1338.Google Scholar

  • 113. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg and M. Gawaz, Effects of statins on platelet inhibition by a high loading dose of clopidogrel, Circulation 108 (2003) 2195-2197.CrossrefGoogle Scholar

  • 114. J. Saw, D. M. Brennan, S. R. Steinhubl, D. L. Bhatt, K. H. Mak, K. Fox and E. J. Topol, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial, J. Am. Coll. Cardiol. 50 (2007) 291-295.CrossrefGoogle Scholar

  • 115. V. L. Serebruany, M. G. Midei, A. I. Malinin, B. R. Oshrine, D. R. Lowry, D. C. Sane, J. F. Tanguay, S. R. Steinhubl, P. B. Berger, C. M. O’Connor and C. H. Hennekens, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study, Arch. Intern. Med. 164 (2004) 2051-2057.CrossrefGoogle Scholar

  • 116. P. Vinholt, T. S. Poulsen, L. Korsholm, S. R. Kristensen, J. Hallas, P. Damkier and H. Mickley, The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease, Thromb. Haemost. 94 (2005) 438-443.Google Scholar

  • 117. A. Zahno, K. Brecht, M. Bodmer, D. Bur, D. A. Tsakiris and S. Krähenbühl, Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro, Br. J. Pharmacol.161 (2010) 393-404; DOI: 10.1111/j.1476-5381.2010.00881.x.CrossrefGoogle Scholar

  • 118. L. R. Whitfield, A. R. Porcari, C. Alvey, R. Abel, W. Bullen and D. Hartman, Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin, J. Clin. Pharmacol. 51 (2011) 378-388; DOI: 10.1177/0091270010366446.CrossrefGoogle Scholar

  • 119. J. S. Wang, M. Neuvonen, X. Wen, J. T. Backman and P. J. Neuvonen, Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes, Drug Metab. Dispos. 30 (2002) 1352-1356.CrossrefGoogle Scholar

  • 120. X. Wen, J. S. Wang, J. T. Backman, K. T. Kivistö and P. J. Neuvonen, Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9, Drug Metab. Dispos. 29 (2001) 1359-1361.Google Scholar

  • 121. H. Fujino, I. Yamada, S. Shimada, M. Hirano, Y. Tsunenari and J. Kojima, Interaction between fibrates and statins - metabolic interactions with gemfibrozil, Drug Metabol. Drug Interact. 19 (2003) 161-176.Google Scholar

  • 122. J. T. Backman, C. Kyrklund, K. T. Kivistö, J. S. Wang and P. J. Neuvonen, Plasma concentrations of active simvastatin acid are increased by gemfibrozil, Clin. Pharmacol. Ther. 68 (2000) 122-129.CrossrefGoogle Scholar

  • 123. T. C. Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams and C. M. Loi, Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid, Drug Metab. Dispos. 35 (2007) 1315-1324.CrossrefGoogle Scholar

  • 124. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate, Clin. Pharmacol. Ther. 69 (2001) 340-345.CrossrefGoogle Scholar

  • 125. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance, Clin. Pharmacol. Ther. 73 (2003) 538-544.CrossrefGoogle Scholar

  • 126. P. Mathew, T. Cuddy, W. G. Tracewell and D. Salazar, An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers, Clin. Pharmacol. Ther. 75 (2004) 33.Google Scholar

  • 127. J. D. Spence, C. E. Munoz, L. Hendricks, L. Latchinian and H. E. Khouri, Pharmacokinetics of the combination of fluvastatin and gemfibrozil, Am. J. Cardiol. 76 (1995) 80A-83A.CrossrefGoogle Scholar

  • 128. N. Bizzaro, E. Bagolin, L. Milani, C. Cereser and B. Finco, Massive rhabdomyolysis and simvastatin, Clin. Chem. 38 (1992) 1504.Google Scholar

  • 129. R. A. Boyd, R. H. Stern, B. H. Stewart, X. Wu, E. L. Reyner, E. A. Zegarac, E. J. Randinitis and L. Whitfield, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion, J. Clin. Pharmacol. 40 (2000) 91-98.CrossrefGoogle Scholar

  • 130. C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. März, J. P. Reckless and E. A. Stein, Risk for myopathy with statin therapy in high-risk patients, Arch. Intern. Med. 163 (2003) 553-564.CrossrefGoogle Scholar

  • 131. P. D. Thompson, P. Clarkson and R. H. Karas, Statin-associated myopathy, JAMA 289 (2003) 1681-1690. CrossrefGoogle Scholar

About the article

Published Online: 2013-10-22

Published in Print: 2013-09-01


Citation Information: Acta Pharmaceutica, ISSN (Online) 1846-9558, ISSN (Print) 1330-0075, DOI: https://doi.org/10.2478/acph-2013-0022.

Export Citation

This content is open access.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Patrick du Souich, Ghislaine Roederer, and Robert Dufour
Pharmacology & Therapeutics, 2017, Volume 175, Page 1
[2]
Janne Hukkanen, Johanna Puurunen, Tuulia Hyötyläinen, Markku J. Savolainen, Aimo Ruokonen, Laure Morin-Papunen, Matej Orešič, Terhi Piltonen, and Juha S. Tapanainen
British Journal of Clinical Pharmacology, 2015, Volume 80, Number 3, Page 473
[3]
S Seo, M Boeckh, B E Storer, M M Schubert, M Rotta, B M Sandmaier, and M Mielcarek
Bone Marrow Transplantation, 2015, Volume 50, Number 3, Page 444
[4]
Ben Verpaalen, Johan Neyts, and Leen Delang
Antiviral Research, 2014, Volume 105, Page 92

Comments (0)

Please log in or register to comment.
Log in